Deep Genomics uses AI to analyse genetic data with the aim of discovering and producing RNA-based genetic medicines. The company is currently running a series of programs with the aim of advancing to clinical trials in the near future.
RNA medical technology has been in development for over 40 years but never became mainstream, but the launch of BioNTech / Pfizer’s Covid-19 vaccine threw it into the public spotlight. This is set to accelerate the production of more and more RNA-based therapeutics, supplemented by AI which can quickly mine dense biological data to better evaluate potential candidates.
With its financial backing in the hundreds of millions, Deep Genomics now intends to radically boost its headcount and roll out more therapeutic discovery programs.
Kirsty
Company Specialist at Welcome to the Jungle